Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of IBI306 in HeFH Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Subjects must meet all of the following inclusion criteria in order to be included in the study:~* Provide a signed and dated informed consent form~* Men or women 18 to 70 years of age at screening~* Weight ≥ 40 kg during screening~* Confirmed diagnosis of heterozygous familial hypercholesterolemia~* Maintain a low-fat diet and stabilize the current lipid-lowering therapy~Exclusion Criteria:~• Subjects who do not meet any of the following exclusion criteria cannot be included in the study:~* Patients diagnosed as homozygous familial hypercholesterolemia~* Dialysis or plasmapheresis performed within 4 months prior to screening~* History of liver transplant~* Subjects adjusted for treatment of statins, ezetimibe, niacin, omega-fatty acids within 4 weeks prior to screening~* New York Heart Association (NYHA) grade III or IV heart failure, or recent detection of left ventricular ejection fraction ≤ 30%~* Have serious cardiovascular, cerebrovascular, liver and kidney related diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- IBI306 (Type: EXPERIMENTAL): Participants received IBI306 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.
- placebo (Type: EXPERIMENTAL): Participants received Placebo 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).